Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 533,184
  • Shares Outstanding, K 93,214
  • Annual Sales, $ 837,600 K
  • Annual Income, $ -127,300 K
  • EBIT $ -82 M
  • EBITDA $ 36 M
  • 60-Month Beta 1.81
  • Price/Sales 0.64
  • Price/Cash Flow 5.92
  • Price/Book 1.48

Options Overview Details

View History
  • Implied Volatility 231.31% (-129.49%)
  • Historical Volatility 40.00%
  • IV Percentile 82%
  • IV Rank 50.30%
  • IV High 407.99% on 12/31/25
  • IV Low 52.48% on 02/20/25
  • Expected Move (DTE 22) 0.49 (8.87%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 1,956
  • Open Int (30-Day) 1,818
  • Expected Range 5.07 to 6.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 4
  • High Estimate -0.10
  • Low Estimate -0.11
  • Prior Year -0.09
  • Growth Rate Est. (year over year) -11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.47 +1.65%
on 01/20/26
7.15 -22.31%
on 01/12/26
-0.76 (-11.97%)
since 12/29/25
3-Month
5.47 +1.65%
on 01/20/26
8.38 -33.71%
on 11/03/25
-2.36 (-29.77%)
since 10/29/25
52-Week
3.76 +47.74%
on 08/01/25
15.47 -64.09%
on 02/19/25
-6.99 (-55.70%)
since 01/29/25

Most Recent Stories

More News
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap...

MYGN : 5.53 (-3.32%)
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm

2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm

MYGN : 5.53 (-3.32%)
MRK : 108.37 (+1.38%)
CAH : 210.54 (+0.07%)
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary...

MYGN : 5.53 (-3.32%)
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and...

MYGN : 5.53 (-3.32%)
3 Stocks Under $10 We Think Twice About

3 Stocks Under $10 We Think Twice About

SSP : 3.46 (+2.98%)
TH : 6.79 (+0.44%)
MYGN : 5.53 (-3.32%)
3 Unprofitable Stocks That Fall Short

3 Unprofitable Stocks That Fall Short

W : 107.55 (-1.05%)
MYGN : 5.53 (-3.32%)
JACK : 20.60 (-1.01%)
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

Myriad Genetics (MYGN) Stock Trades Up, Here Is Why

MYGN : 5.53 (-3.32%)
Why Myriad Genetics (MYGN) Stock Is Up Today

Why Myriad Genetics (MYGN) Stock Is Up Today

MYGN : 5.53 (-3.32%)
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium

SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight...

MYGN : 5.53 (-3.32%)
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings?

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings?

MYGN : 5.53 (-3.32%)

Business Summary

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made...

See More

Key Turning Points

3rd Resistance Point 6.15
2nd Resistance Point 6.05
1st Resistance Point 5.88
Last Price 5.53
1st Support Level 5.62
2nd Support Level 5.52
3rd Support Level 5.36

See More

52-Week High 15.47
Fibonacci 61.8% 11.00
Fibonacci 50% 9.61
Fibonacci 38.2% 8.23
Last Price 5.53
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar